SPRY — ARS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $429.61m
- $382.44m
- $84.28m
ARS Pharma rises on surprise Q4 profit
ARS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Fastenal, Target Hospitality , Encore Capital
U.S. STOCKS ON THE MOVE-CoreCivic, Teladoc, Dynavax
U.S. STOCKS ON THE MOVE-Scienture, ARS Pharma, BrightSpring Health
ARS Pharma rises on expanded US approval for allergic reaction nasal spray
Brief: ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions
US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms (updated)
US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms
Brief: Ars Pharmaceuticals Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Brief: ARS Pharmaceuticals Announces Filings For Approval Of Neffy In China, Japan And Australia
Brief: Neurelis Enters $208 Million Agreement To Monetize Intravail Royalties
ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: ARS Pharmaceuticals Reports Q3 2024 Financial Results And Provides Business Updates
ARS Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Alk Says Co Licenses Rights To Neffy
Brief: ARS Pharmaceuticals Says Unit Entered Supply Agreement With Nuova Ompi SRL
Brief: ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Brief: Ars Pharmaceuticals Submits SNDA To FDA For Neffy® 1 Mg Dose For Pediatric Patients With Type I Allergic Reactions Who Weigh 15 To 30 KG (33-66 Lbs.)